Evidence map›Paper›PMID 35627293›Full record

ArticleGenes2022

Novel Loss-of-Function Variants in

Xu Wang, Di Cui, Changhong Ding, Chunhong Chen, Xiaohui Wang, Fang Fang, Hong Jin, Xiaotun Ren

Open access · goldAbstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Chromodomain helicase DNA-binding proteins and orofacial cleft.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xu WangDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.ORCID 0000-0002-3691-8468
Di CuiRunning Gene Inc., Beijing, 100085, China.
Changhong DingDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
Chunhong ChenDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
Xiaohui WangDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
Fang FangDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
Hong JinDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
Xiaotun RenDepartment of Neurology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing 100045, China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developmental and epileptic encephalopathy-94 (DEE94) is a severe form of epilepsy characterized by a broad spectrum of neurodevelopmental disorders. It is caused by pathogenic CHD2 variants. While only a few pathogenic CHD2 variants have been reported with detailed clinical phenotypes, most of which lack molecular analysis. In this study, next-generation sequencing (NGS) was performed to identify likely pathogenic CHD2 variants in patients with epilepsy. Three likely pathogenic variants were finally identified in different patients. The seizure onset ages were from two years to six years. Patients 1 and 2 had developmental delays before epilepsy, while patient 3 had intellectual regression after the first seizure onset. The observed seizures were myoclonic, febrile, and generalized tonic-clonic, which had been controlled by different combinations of antiepileptic drugs. Two de novo (c.1809_1809+1delGGinsTT, p.? and c.3455+2_3455+3insTG, p.?) and one maternal (c.3783G>A, p.W1261*) variant were identified, which were all predicted to be pathogenic/likely pathogenic. Molecular analysis was performed in patient 1, and we detected aberrantly spliced products, proving the pathogenicity of this CHD2 variant. New cases with novel variants, along with a detailed clinical and molecular analysis, are important for a better understanding of CHD2-related epileptic encephalopathy.

Indexed as

DNA-Binding ProteinsEpilepsyAsian PeopleChildChinaHumansPhenotypeSeizuresCHD2 protein, humanDNA-Binding Proteinschildhood-onset epileptic encephalopathy (DEE94)chromodomain-helicase-DNA-binding protein 2 (CHD2)developmental delayepileptic encephalopathy (EE)intellectual disability (ID)seizure

Identifiers

PMID35627293
PMCPMC9140428
OpenAlexW4280579769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.